-
Something wrong with this record ?
Reversible suppression of sexual activity in tomcats with deslorelin implant
R. Novotny, P. Cizek, R. Vitasek, A. Bartoskova, P. Prinosilova, M. Janosovska,
Language English Country United States
Document type Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Contraception methods veterinary MeSH
- Down-Regulation drug effects MeSH
- Ejaculation drug effects physiology MeSH
- Drug Implants MeSH
- Cats * anatomy & histology blood physiology MeSH
- Contraceptive Agents, Male administration & dosage MeSH
- Withholding Treatment MeSH
- Recovery of Function drug effects physiology MeSH
- Osmolar Concentration MeSH
- Sexual Behavior, Animal drug effects physiology MeSH
- Testis anatomy & histology drug effects physiology MeSH
- Testosterone blood MeSH
- Triptorelin Pamoate administration & dosage analogs & derivatives MeSH
- Organ Size drug effects MeSH
- Animals MeSH
- Check Tag
- Cats * anatomy & histology blood physiology MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Controlled Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
The aim of the study was to assess the efficacy of using a Gn-RH agonist implant (deslorelin, 4.7 mg, Suprelorin) to control sexual activity of male cats and reestablishment of sexual function after the implant removal 4 mo after placement. Using a control group (Group 1, n = 5), 22 domestic tomcats were given the implant subcutaneously in the region of the right shoulder blade and were then divided into two treatment groups. Animals in Group 2 (n = 14) were observed from the date of implant surgery and the observation lasted for 4 mo. In Group 3 (n = 8) all animals were monitored from the date of implant surgery. Then, after 4 mo, all implants were removed and the toms were observed for a further 4 mo. In all animals during their first visit and then in 1-mo intervals, changes in testosterone concentrations were assessed before (T0) and 4 h after (T4) human chorionic gonadotropin (HCG) administration and testis size was measured. In all tomcats, semen collection was performed, using an electroejaculator, in the course of the first visit and then in 2-mo intervals or at the end of observation. Total sperm count was determined in each semen sample. Two to four animals were castrated at weeks 4, 8, 12, 16, 20, 24, 28 and 32 and histologic assessment of the testes was performed. By evaluation of 200 cross sections of seminiferous tubules, the degree of spermatogenic suppression was assessed and animals in Groups 2 and 3 were assigned into groups according to most tubules with the most developed germ cell observed: G1, spermatocytes; G2, round spermatids; G3, elongating spermatids and G4, elongated spermatids. The mean area of Leydig-cell nuclei was calculated. In animals in Group 2, suppression after implant insertion was monitored. T4 concentrations, testis size, and total sperm count gradually decreased (P < 0.01; P < 0.01; and P < 0.05, respectively) within 4 mo after implantation. Histologic evaluation showed a high individual variation in the degree of suppression of spermatogenesis. In animals in Group 3, the implant was removed 4 mo after insertion and the return of sexual activity was monitored. Within 4 mo, T4 concentration and total sperm count increased to the physiological values of intact toms. Testes gradually increased in size and within 4 mo of implant removal almost reached pretreatment size. According to histologic evaluation of the seminiferous tubules, as early as 1 mo after implant removal, all animals were assigned to G4, with most tubules containing elongated spermatids as the most developed germ cells. Treatment with the long-term subcutaneous Gn-RH agonist implant was well tolerated and no adverse treatment-related effects were noted. These results demonstrated efficacy of 4.7 mg deslorelin implant (Suprelorin) with high variability of the effect onset in tomcats. Furthermore, the study revealed a strong need for complex examination, including testis size measurement, monitoring of hormonal changes, spermatological analysis and histologic evaluation, to declare the animal infertile. After the implant removal, all observed parameters confirmed the reversibility of the method and gradual return of sexual activity in toms.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13012684
- 003
- CZ-PrNML
- 005
- 20130415123707.0
- 007
- ta
- 008
- 130404s2012 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.theriogenology.2012.03.035 $2 doi
- 035 __
- $a (PubMed)22578617
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Novotny, R $u Department of Reproduction, Clinic of Dog and Cat Diseases, University of Veterinary and Pharmaceutical Sciences, Brno, Brno, Czech Republic. novotnyr@vfu.cz
- 245 10
- $a Reversible suppression of sexual activity in tomcats with deslorelin implant / $c R. Novotny, P. Cizek, R. Vitasek, A. Bartoskova, P. Prinosilova, M. Janosovska,
- 520 9_
- $a The aim of the study was to assess the efficacy of using a Gn-RH agonist implant (deslorelin, 4.7 mg, Suprelorin) to control sexual activity of male cats and reestablishment of sexual function after the implant removal 4 mo after placement. Using a control group (Group 1, n = 5), 22 domestic tomcats were given the implant subcutaneously in the region of the right shoulder blade and were then divided into two treatment groups. Animals in Group 2 (n = 14) were observed from the date of implant surgery and the observation lasted for 4 mo. In Group 3 (n = 8) all animals were monitored from the date of implant surgery. Then, after 4 mo, all implants were removed and the toms were observed for a further 4 mo. In all animals during their first visit and then in 1-mo intervals, changes in testosterone concentrations were assessed before (T0) and 4 h after (T4) human chorionic gonadotropin (HCG) administration and testis size was measured. In all tomcats, semen collection was performed, using an electroejaculator, in the course of the first visit and then in 2-mo intervals or at the end of observation. Total sperm count was determined in each semen sample. Two to four animals were castrated at weeks 4, 8, 12, 16, 20, 24, 28 and 32 and histologic assessment of the testes was performed. By evaluation of 200 cross sections of seminiferous tubules, the degree of spermatogenic suppression was assessed and animals in Groups 2 and 3 were assigned into groups according to most tubules with the most developed germ cell observed: G1, spermatocytes; G2, round spermatids; G3, elongating spermatids and G4, elongated spermatids. The mean area of Leydig-cell nuclei was calculated. In animals in Group 2, suppression after implant insertion was monitored. T4 concentrations, testis size, and total sperm count gradually decreased (P < 0.01; P < 0.01; and P < 0.05, respectively) within 4 mo after implantation. Histologic evaluation showed a high individual variation in the degree of suppression of spermatogenesis. In animals in Group 3, the implant was removed 4 mo after insertion and the return of sexual activity was monitored. Within 4 mo, T4 concentration and total sperm count increased to the physiological values of intact toms. Testes gradually increased in size and within 4 mo of implant removal almost reached pretreatment size. According to histologic evaluation of the seminiferous tubules, as early as 1 mo after implant removal, all animals were assigned to G4, with most tubules containing elongated spermatids as the most developed germ cells. Treatment with the long-term subcutaneous Gn-RH agonist implant was well tolerated and no adverse treatment-related effects were noted. These results demonstrated efficacy of 4.7 mg deslorelin implant (Suprelorin) with high variability of the effect onset in tomcats. Furthermore, the study revealed a strong need for complex examination, including testis size measurement, monitoring of hormonal changes, spermatological analysis and histologic evaluation, to declare the animal infertile. After the implant removal, all observed parameters confirmed the reversibility of the method and gradual return of sexual activity in toms.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a kočky $x anatomie a histologie $x krev $x fyziologie $7 D002415
- 650 _2
- $a antikoncepce $x metody $x veterinární $7 D003267
- 650 _2
- $a kontraceptiva mužská $x aplikace a dávkování $7 D003272
- 650 _2
- $a down regulace $x účinky léků $7 D015536
- 650 _2
- $a implantované léky $7 D004343
- 650 _2
- $a ejakulace $x účinky léků $x fyziologie $7 D004542
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a velikost orgánu $x účinky léků $7 D009929
- 650 _2
- $a osmolární koncentrace $7 D009994
- 650 _2
- $a obnova funkce $x účinky léků $x fyziologie $7 D020127
- 650 _2
- $a sexuální chování zvířat $x účinky léků $x fyziologie $7 D012726
- 650 _2
- $a testis $x anatomie a histologie $x účinky léků $x fyziologie $7 D013737
- 650 _2
- $a testosteron $x krev $7 D013739
- 650 _2
- $a triptorelin-pamoát $x aplikace a dávkování $x analogy a deriváty $7 D017329
- 650 _2
- $a nenasazení léčby $7 D028761
- 655 _2
- $a klinické zkoušky kontrolované $7 D018848
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Cizek, P $u -
- 700 1_
- $a Vitasek, R $u -
- 700 1_
- $a Bartoskova, A $u -
- 700 1_
- $a Prinosilova, P $u -
- 700 1_
- $a Janosovska, M $u -
- 773 0_
- $w MED00004512 $t Theriogenology $x 1879-3231 $g Roč. 78, č. 4 (2012), s. 848-57
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22578617 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130404 $b ABA008
- 991 __
- $a 20130415123940 $b ABA008
- 999 __
- $a ok $b bmc $g 975882 $s 810965
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 78 $c 4 $d 848-57 $i 1879-3231 $m Theriogenology $n Theriogenology $x MED00004512
- LZP __
- $a Pubmed-20130404